Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Enteric-coated mycophenolate sodium could be an alternative to methotrexate for GVHD prophylaxis.

In English

Författare

Summary, in English

Morbidity and mortality resulting from acute and subsequently chronic graft-versus-host disease (GVHD) pose a serious challenge to wider applicability of allogeneic stem cell transplantation (SCT). Mycophenolate mofetil (MMF) is a widely used drug in combination with a calcineurin inhibitor and often cyclosporine (CsA), in preventing GVHD. The use of MMF for acute GVHD (aGVHD) prophylaxis appears to result in significantly faster platelet engraftment and a lower incidence of severe mucositis compared to methotrexate, which could reduce the length of hospital stay. However, there is no statistically significant difference between MMF and methotrexate in regards to relapse risk, non-relapse mortality, or overall survival(1) . This article is protected by copyright. All rights reserved.

Publiceringsår

2016

Språk

Engelska

Sidor

213-214

Publikation/Tidskrift/Serie

European Journal of Haematology

Volym

97

Issue

3

Dokumenttyp

Artikel i tidskrift

Förlag

Wiley-Blackwell

Ämne

  • Hematology

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1600-0609